ICER Releases Draft Evidence Report on Treatment for Pulmonary Arterial Hypertension

— Registration now open for October 5th “Early Insights” webinar —

— Public comment period now open until October 23, 2023; Requests to make oral comment during public meeting also being accepted —

BOSTON, September 25, 2023 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of sotatercept (Merck & Co) for pulmonary arterial hypertension. This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.

On October 5, 2023, as part of ICER’s Early Insights Webinar Series, ICER’s Chief Medical Officer, David Rind, MD will present the initial findings of this draft report. This webinar is exclusively available to all users of the ICER Analytics platform; registration for the webinar is now open.

Submit a Public Comment

The Draft Evidence Report and Draft Voting Questions are now open to public comment. All stakeholders are invited to submit formal comments by email to publiccomments@icer.org, which must be received by 5 PM ET on October 23, 2023. Please submit public comments as a Word document in the following format:

12-point Times New Roman font

Five-page maximum (not including references or appendices)

ICER’s Manufacturer Engagement Guide and Patient Portal provide additional detail on what types of information may be most informative to the report.

ICER will review all comments and incorporate any necessary changes in the Evidence Report and Revised Voting Questions that will be posted on or about November 14, 2023. All comments and ICER’s response to comments will be posted publicly along with the Evidence Report.

The Evidence Report will be the subject of a virtual public meeting of Midwest CEPAC on December 1, 2023. During the meeting, the independent council will vote on key questions raised in the report. Registration for the virtual public meeting is now open.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.